362 related articles for article (PubMed ID: 26644586)
1. BRD4 is a novel therapeutic target for liver fibrosis.
Ding N; Hah N; Yu RT; Sherman MH; Benner C; Leblanc M; He M; Liddle C; Downes M; Evans RM
Proc Natl Acad Sci U S A; 2015 Dec; 112(51):15713-8. PubMed ID: 26644586
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage.
Suarez-Alvarez B; Morgado-Pascual JL; Rayego-Mateos S; Rodriguez RM; Rodrigues-Diez R; Cannata-Ortiz P; Sanz AB; Egido J; Tharaux PL; Ortiz A; Lopez-Larrea C; Ruiz-Ortega M
J Am Soc Nephrol; 2017 Feb; 28(2):504-519. PubMed ID: 27436852
[TBL] [Abstract][Full Text] [Related]
3. Bromodomain-containing protein 4 contributes to renal fibrosis through the induction of epithelial-mesenchymal transition.
Wang X; Zhou Y; Peng Y; Huang T; Xia F; Yang T; Duan Q; Zhang W
Exp Cell Res; 2019 Oct; 383(2):111507. PubMed ID: 31356816
[TBL] [Abstract][Full Text] [Related]
4. Dynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation.
Stratton MS; Bagchi RA; Felisbino MB; Hirsch RA; Smith HE; Riching AS; Enyart BY; Koch KA; Cavasin MA; Alexanian M; Song K; Qi J; Lemieux ME; Srivastava D; Lam MPY; Haldar SM; Lin CY; McKinsey TA
Circ Res; 2019 Sep; 125(7):662-677. PubMed ID: 31409188
[TBL] [Abstract][Full Text] [Related]
5. Early-immediate gene Egr1 is associated with TGFβ1 regulation of epigenetic reader Bromodomain-containing protein 4 via the canonical Smad3 signaling in hepatic stellate cells in vitro and in vivo.
Tian H; Xu F; Zhao F; Pan N; Lu S; Jia X; Zhou Y
FASEB J; 2022 Nov; 36(11):e22605. PubMed ID: 36250963
[TBL] [Abstract][Full Text] [Related]
6. Bromodomain protein 4 is a key molecular driver of TGFβ1-induced hepatic stellate cell activation.
Xu F; Lu S; Pan N; Zhao F; Jia X; Wang S; Zhang Y; Zhou Y
Biochim Biophys Acta Mol Cell Res; 2023 Dec; 1870(8):119569. PubMed ID: 37597774
[TBL] [Abstract][Full Text] [Related]
7. Brd4 inhibition attenuates unilateral ureteral obstruction-induced fibrosis by blocking TGF-β-mediated Nox4 expression.
Zhou B; Mu J; Gong Y; Lu C; Zhao Y; He T; Qin Z
Redox Biol; 2017 Apr; 11():390-402. PubMed ID: 28063381
[TBL] [Abstract][Full Text] [Related]
8. Pharmacoproteomics reveal novel protective activity of bromodomain containing 4 inhibitors on vascular homeostasis in TLR3-mediated airway remodeling.
Zhao Y; Tian B; Sun H; Zhang J; Zhang Y; Ivannikov M; Motamedi M; Liu Z; Zhou J; Kaphalia L; Calhoun WJ; Maroto R; Brasier AR
J Proteomics; 2019 Aug; 205():103415. PubMed ID: 31195152
[TBL] [Abstract][Full Text] [Related]
9. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
10. Brd4-p300 inhibition downregulates Nox4 and accelerates lung fibrosis resolution in aged mice.
Sanders YY; Lyv X; Zhou QJ; Xiang Z; Stanford D; Bodduluri S; Rowe SM; Thannickal VJ
JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32544088
[TBL] [Abstract][Full Text] [Related]
11. BRD4 suppression alleviates cerebral ischemia-induced brain injury by blocking glial activation via the inhibition of inflammatory response and pyroptosis.
Zhou Y; Gu Y; Liu J
Biochem Biophys Res Commun; 2019 Nov; 519(3):481-488. PubMed ID: 31530390
[TBL] [Abstract][Full Text] [Related]
12. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
[TBL] [Abstract][Full Text] [Related]
13. Prevention of hepatic stellate cell activation using JQ1- and atorvastatin-loaded chitosan nanoparticles as a promising approach in therapy of liver fibrosis.
Hassan R; Tammam SN; Safy SE; Abdel-Halim M; Asimakopoulou A; Weiskirchen R; Mansour S
Eur J Pharm Biopharm; 2019 Jan; 134():96-106. PubMed ID: 30471341
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-29a is a key regulon that regulates BRD4 and mitigates liver fibrosis in mice by inhibiting hepatic stellate cell activation.
Huang YH; Kuo HC; Yang YL; Wang FS
Int J Med Sci; 2019; 16(2):212-220. PubMed ID: 30745801
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis.
Tang X; Peng R; Phillips JE; Deguzman J; Ren Y; Apparsundaram S; Luo Q; Bauer CM; Fuentes ME; DeMartino JA; Tyagi G; Garrido R; Hogaboam CM; Denton CP; Holmes AM; Kitson C; Stevenson CS; Budd DC
Am J Pathol; 2013 Aug; 183(2):470-9. PubMed ID: 23759512
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer.
Hong SH; Eun JW; Choi SK; Shen Q; Choi WS; Han JW; Nam SW; You JS
Oncotarget; 2016 May; 7(22):32628-40. PubMed ID: 27081696
[TBL] [Abstract][Full Text] [Related]
17. SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer.
Joshi S; Singh AR; Liu KX; Pham TV; Zulcic M; Skola D; Chun HB; Glass CK; Morales GA; Garlich JR; Durden DL
Mol Cancer Ther; 2019 Jun; 18(6):1036-1044. PubMed ID: 31018997
[TBL] [Abstract][Full Text] [Related]
18. BRD4 promotes hepatic stellate cells activation and hepatic fibrosis via mediating P300/H3K27ac/PLK1 axis.
Cheng M; Li JJ; Niu XN; Zhu L; Liu JY; Jia PC; Zhu S; Meng HW; Lv XW; Huang C; Li J
Biochem Pharmacol; 2023 Apr; 210():115497. PubMed ID: 36907496
[TBL] [Abstract][Full Text] [Related]
19. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
[TBL] [Abstract][Full Text] [Related]
20. Targeting Mechanotransduction at the Transcriptional Level: YAP and BRD4 Are Novel Therapeutic Targets for the Reversal of Liver Fibrosis.
Zhubanchaliyev A; Temirbekuly A; Kongrtay K; Wanshura LC; Kunz J
Front Pharmacol; 2016; 7():462. PubMed ID: 27990121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
